ipjno

Journal of Neuro-Oncology and Neuroscience

ISSN - 2572-0376

Research Article - (2019) Volume 4, Issue 1

Expectation and Preferences with Palliative Systemic Therapy in Recurrent Gliomas

 

Author info »

Abstract

Background: Expectation and preferences of recurrent glioma patients are rarely captured and hence are ill reported in literature. To overcome the above-mentioned deficiency, we undertook a study to capture the expectation and preferences of recurrent glioma patients.

Methods: This was cross-sectional study, with the expectation and preferences, of 40 recurrent glioma patients were captured at a single visit post counseling about the disease prognosis and treatment options. SPSS version 16 and RStudio version 3.4.2 was used for analysis and descriptive statistics was performed.

Results: Prolongation of life as alone or in combination with symptom control was the primary expectation in 90% of patients (n=36, 95% CI 76.2-96.5). The median time patients preferred to devote out of the remaining life span for home, work and hospital were 60% (IQR 60-90), 32.5% (IQR 1.25-50) and 0% (IQR 0-10) respectively. The adverse event most feared by patients and hence not preferred were skin rash (7, 17.5%), numbness (7, 17.5%) and vomiting (6, 15%). Majority of patients (67.5%, 27) were willing to trade off a survival of >4 months for a cheaper regimen if necessitated. Ninety-five (38) percent of patients were willing to participate in the research protocols if they are available.

Conclusion: Prolongation of life either alone or along with symptom control is the primary expectation from systemic therapy of recurrent glioma patients.

References

  1. Patil V, Joshi A, Noronha V, Deodhar J, Bhattacharjee A, et al. (2016) Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncol 63: 10-15.
  2. Blanchard P, Volk RJ, Ringash J, Peterson SK, Hutcheson KA, et al. (2016) Assessing head and neck cancer patient preferences and expectations: A systematic review. Oral Oncol 62: 44-53.
  3. Smith TJ, Dow LA, Virago EA, Khatcheressian J, Matsuyama R, et al. (2011) A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol 9: 79-86.
  4. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, et al. (2016) Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 34: 2925-2934.
  5. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, et al. (2017) ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 28: 2340-2366.
  6. Kendall M, Carduff E, Lloyd A, Kimbell B, Cavers D, et al. (2015) Different Experiences and Goals in Different Advanced Diseases: Comparing Serial Interviews with Patients with Cancer, Organ Failure, or Frailty and their Family and Professional Careers. J Pain Symptom Manage 50: 216-224.
  7. Patil VM, Chakraborty S, Jithin TK, Dessai S, Sajith Babu TP, et al. (2016) Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire. Indian J Cancer 53: 339-344.
  8. Diamond EL, Corner GW, De Rosa A, Breitbart W, Applebaum AJ, et al. (2014) Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review. J Neurooncol 119: 227-234.

Author Info

 

, DOI: 10.36648/2572-0376.4.1.25

Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.